A
Alberto Bardelli
Researcher at University of Turin
Publications - 382
Citations - 59190
Alberto Bardelli is an academic researcher from University of Turin. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 95, co-authored 340 publications receiving 50556 citations. Previous affiliations of Alberto Bardelli include University of Milan & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda,Chetan Bettegowda,Mark Sausen,Rebecca J. Leary,Isaac Kinde,Yuxuan Wang,Nishant Agrawal,Nishant Agrawal,Bjarne Bartlett,Bjarne Bartlett,Hao Wang,Brandon Luber,Rhoda M. Alani,Emmanuel S. Antonarakis,Nilofer S. Azad,Alberto Bardelli,Henry Brem,John L. Cameron,Clarence Lee,Leslie A. Fecher,Leslie A. Fecher,Gary L. Gallia,Peter Gibbs,Dung T. Le,Dung T. Le,Robert L. Giuntoli,Michael Goggins,Michael D. Hogarty,Matthias Holdhoff,Seung-Mo Hong,Seung-Mo Hong,Yuchen Jiao,Hartmut Juhl,Jenny J. Kim,Giulia Siravegna,Daniel A. Laheru,Calogero Lauricella,Michael Lim,Evan J. Lipson,Suely Kazue Nagahashi Marie,George J. Netto,Kelly S. Oliner,Alessandro Olivi,Louise Olsson,Gregory J. Riggins,Andrea Sartore-Bianchi,Kerstin Schmidt,le-Ming Shih,Sueli Mieko Oba-Shinjo,Salvatore Siena,Dan Theodorescu,Jeanne Tie,Timothy T. Harkins,Silvio Veronese,Tian Li Wang,Jon D. Weingart,Christopher L. Wolfgang,Laura D. Wood,Dongmei Xing,Ralph H. Hruban,Jian Wu,Peter J. Allen,C. Max Schmidt,Michael A. Choti,Victor E. Velculescu,Kenneth W. Kinzler,Bert Vogelstein,Nickolas Papadopoulos,Luis A. Diaz,Luis A. Diaz +69 more
TL;DR: The ability of circulating tumor DNA (ctDNA) to detect tumors in 640 patients with various cancer types was evaluated and suggested that ctDNA is a broadly applicable, sensitive, and specific biomarker that can be used for a variety of clinical and research purposes.
Journal ArticleDOI
High frequency of mutations of the PIK3CA gene in human cancers
Yardena Samuels,Zhenghe Wang,Alberto Bardelli,Natalie Silliman,Janine Ptak,Steve Szabo,Hai Yan,Adi F. Gazdar,Steven M. Powell,Gregory J. Riggins,James K V Willson,Sanford D. Markowitz,Kenneth W. Kinzler,Bert Vogelstein,Victor E. Velculescu +14 more
TL;DR: To determine if PI3Ks are genetically altered in tumorigenesis, they were sequenced in human for the first time and the results allowed us to assess the importance of phosphatidylinositol 3-kinases in neoplasia.
Journal ArticleDOI
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem,Andrés Cervantes,René Adam,Alberto Sobrero,J.H.J.M. van Krieken,Dan Aderka,E. Aranda Aguilar,Alberto Bardelli,Al B. Benson,György Bodoky,Fortunato Ciardiello,André D'Hoore,Eduardo Díaz-Rubio,J.-Y. Douillard,Michel Ducreux,Alfredo Falcone,Axel Grothey,Thomas Gruenberger,Karin Haustermans,Volker Heinemann,Paulo M. Hoff,C.-H. Köhne,R. Labianca,Pierre Laurent-Puig,Brigette B.Y. Ma,Tim Maughan,Kei Muro,Nicola Normanno,Pia Österlund,Pia Österlund,Wim J.G. Oyen,Demetris Papamichael,George Pentheroudakis,Per Pfeiffer,Timothy J. Price,C.J.A. Punt,Jens Ricke,Arnaud Roth,R. Salazar,Werner Scheithauer,H.-J. Schmoll,Josep Tabernero,Julien Taieb,Sabine Tejpar,Harpreet Wasan,Takayuki Yoshino,Aziz Zaanan,Dirk Arnold +47 more
TL;DR: These ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.
Journal ArticleDOI
International network of cancer genome projects
Thomas J. Hudson,Thomas J. Hudson,Warwick Anderson,Axel Aretz,Anna D. Barker,Cindy Bell,Rosa R. Bernabé,Maharaj K. Bhan,Fabien Calvo,Iiro Eerola,Daniela S. Gerhard,Alan E. Guttmacher,Mark S. Guyer,Fiona M. Hemsley,Jennifer L. Jennings,David J. Kerr,Peter Klatt,Patrik Kolar,Jun Kusuda,David P. Lane,Frank Laplace,Youyong Lu,Gerd Nettekoven,Brad Ozenberger,Jane Peterson,T. S. Rao,Jacques Remacle,Alan J. Schafer,Tatsuhiro Shibata,Michael R. Stratton,Joseph G. Vockley,Koichi Watanabe,Huanming Yang,Matthew Ming Fai Yuen,Bartha Maria Knoppers,Martin Bobrow,Anne Cambon-Thomsen,Lynn G. Dressler,Stephanie O.M. Dyke,Yann Joly,Kazuto Kato,Karen Kennedy,Pilar Nicolás,Michael Parker,Emmanuelle Rial-Sebbag,Carlos M. Romeo-Casabona,Kenna M. Shaw,Susan E. Wallace,Georgia L. Wiesner,Nikolajs Zeps,Peter Lichter,Andrew V. Biankin,Andrew V. Biankin,Christian Chabannon,Lynda Chin,Bruno Clément,Enrique de Alava,Françoise Degos,Martin L. Ferguson,Peter Geary,D. Neil Hayes,Amber L. Johns,Arek Kasprzyk,Hidewaki Nakagawa,Robert Penny,Miguel A. Piris,Rajiv Sarin,Aldo Scarpa,Marc J. van de Vijver,Marc J. van de Vijver,P. Andrew Futreal,Hiroyuki Aburatani,Mònica Bayés,David D.L. Bowtell,David D.L. Bowtell,Peter J. Campbel,Peter J. Campbel,Xavier Estivill,Sean M. Grimmond,Ivo Gut,Martin Hirst,Carlos López-Otý́n,Partha P. Majumder,Marco A. Marra,John Douglas Mcpherson,John Douglas Mcpherson,Zemin Ning,Xose S. Puente,Yijun Ruan,Hendrik G. Stunnenberg,Harold Swerdlow,Victor E. Velculescu,Richard K. Wilson,Hong Xue,Liu Yang,Paul T. Spellman,Gary D. Bader,Paul C. Boutros,Paul Flicek,Gad Getz,Roderic Guigó,Guangwu Guo,David Haussler,Simon Heath,Tim Hubbard,Tao Jiang,Steven J. M. Jones,Qibin Li,Nuria Lopez-Bigas,Ruibang Luo,Lakshmi Muthuswamy,B. F. Francis Ouellette,John V. Pearson,Víctor Quesada,Benjamin J. Raphael,Chris Sander,Terence P. Speed,Terence P. Speed,Lincoln Stein,Joshua M. Stuart,Jon W. Teague,Yasushi Totoki,Tatsuhiko Tsunoda,Alfonso Valencia,David A. Wheeler,Honglong Wu,Shancen Zhao,Guangyu Zhou,Mark Lathrop,Gilles Thomas,Teruhiko Yoshida,Myles Axton,Chris Gunter,Linda Miller,Junjun Zhang,Syed Haider,Jianxin Wang,Christina K. Yung,Anthony Cross,Yong Liang,Saravanamuttu Gnaneshan,Jonathan M. Guberman,Jack Hsu,Don Chalmers,Karl W. Hasel,Terry Sheung-Hung Kaan,William W. Lowrance,Tohru Masui,Laura Lyman Rodriguez,Catherine Vergely,David D.L. Bowtel,Nicole Cloonan,Anna deFazio,Anna deFazio,James R. Eshleman,Dariush Etemadmoghadam,Dariush Etemadmoghadam,Brooke A. Gardiner,James G. Kench,James G. Kench,Robert L. Sutherland,Margaret A. Tempero,Nicola Waddell,Peter Wilson,Steve Gallinger,Steve Gallinger,Ming-Sound Tsao,Ming-Sound Tsao,Patricia Shaw,Gloria M. Petersen,Debabrata Mukhopadhyay,Ronald A. DePinho,Sarah P. Thayer,Kamran Shazand,Timothy Beck,Michelle Sam,Lee Timms,Vanessa Ballin,Jiafu Ji,Xiuqing Zhang,Feng Chen,Xueda Hu,Qi Yang,Geng Tian,Lianhai Zhang,Xiaofang Xing,Xianghong Li,Zhenggang Zhu,Yingyan Yu,Jun Yu,Jörg Tost,Paul Brennan,Ivana Holcatova,David Zaridze,Alvis Brazma,Lars Egevad,Egor Prokhortchouk,Rosamonde E. Banks,Mathias Uhlén,Juris Viksna,Fredrik Pontén,Konstantin G. Skryabin,P. Andrew Futrea,Ewan Birney,Åke Borg,Anne Lise Børresen-Dale,Carlos Caldas,John A. Foekens,Sancha Martin,Jorge S. Reis-Filho,Andrea L. Richardson,Christos Sotiriou,Laura van 't Veer,Daniel Birnbaum,Hélène Blanché,Pascal Boucher,Sandrine Boyault,Jocelyne D. Masson-Jacquemier,Iris Pauporté,Xavier Pivot,Anne Vincent-Salomon,Eric Tabone,Charles Theillet,Isabelle Treilleux,Paulette Bioulac-Sage,Thomas Decaens,Franc OiseDegos,Dominique Franco,Gut M,Didier Samuel,Jessica Zucman-Rossi,Roland Eils,Roland Eils,Benedikt Brors,Jan O. Korbe,Andrey Korshunov,Pablo Landgraf,Hans Lehrach,Stefan M. Pfister,Stefan M. Pfister,Bernhard Radlwimmer,Guido Reifenberger,Michael D. Taylor,Christof von Kalle,Partha P. Majumder,Paolo Pederzoli,Rita T. Lawlor,Massimo Delledonne,Alberto Bardelli,Thomas M. Gress,David S. Klimstra,Giuseppe Zamboni,Yusuke Nakamura,Satoru Miyano,Akihiro Fujimoto,Elias Campo,Silvia de Sanjosé,Emili Montserrat,Marcos González-Dý́az,Pedro Jares,Heinz Himmelbaue,Sílvia Beà,Samuel Aparicio,Douglas F. Easton,Francis S. Collins,Carolyn C. Compton,Eric S. Lander,Wylie Burke,Anthony R. Green,Stanley R. Hamilton,Olli Kallioniemi,Timothy J. Ley,Edison T. Liu,Brandon J. Wainwright +273 more
TL;DR: Systematic studies of more than 25,000 cancer genomes will reveal the repertoire of oncogenic mutations, uncover traces of the mutagenic influences, define clinically relevant subtypes for prognosis and therapeutic management, and enable the development of new cancer therapies.
Journal ArticleDOI
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock,Bart Claes,David Bernasconi,Jef De Schutter,Bart Biesmans,George Fountzilas,Konstantine T. Kalogeras,Vassiliki Kotoula,Demetris Papamichael,Pierre Laurent-Puig,Frédérique Penault-Llorca,Philippe Rougier,Bruno Vincenzi,Daniele Santini,Giuseppe Tonini,Federico Cappuzzo,Milo Frattini,Francesca Molinari,Piercarlo Saletti,Sara De Dosso,Miriam Martini,Alberto Bardelli,Salvatore Siena,Andrea Sartore-Bianchi,Josep Tabernero,Teresa Macarulla,Frédéric Di Fiore,Alice Gangloff,Fortunato Ciardiello,Per Pfeiffer,Camilla Qvortrup,Tine Plato Hansen,Eric Van Cutsem,Hubert Piessevaux,Diether Lambrechts,Mauro Delorenzi,Mauro Delorenzi,Sabine Tejpar +37 more
TL;DR: This is the largest cohort to date of patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab plus chemotherapy in the pre-KRAS selection era and confirmed that, if KRAS is not mutated, assessing BRAF, NRAS, and PIK3CA population response rates confirmed that.